<DOC>
	<DOCNO>NCT00206661</DOCNO>
	<brief_summary>The purpose study observe pediatric Crohn 's Disease response sargramostim patient without steroid therapy two possible dosage level .</brief_summary>
	<brief_title>Safety Efficacy Study Treatment Pediatric Crohn 's Disease</brief_title>
	<detailed_description>On 29 May 2009 , Bayer begin transition sponsorship trial Genzyme . NOTE : This study originally post sponsor Berlex , Inc. Berlex , Inc. rename Bayer HealthCare , Inc .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Have parent guardian able provide write informed consent Be able provide verbal write assent depend age Age 6 16 year Have confirm diagnosis Crohn 's Disease study time study entry base radiologic , endoscopic , histologic evaluation Have PCDAI score &gt; /= 30 point Have negative serum pregnancy test within 7 day prior receive first dose sargramostim female patient , opinion investigator , sexually active childbearing potential Be able selfinject sargramostim designee Available documentation weight 4 6 month prior study entry Existing colostomy ileostomy Immediate need GI surgery active GI bleeding , peritonitis , intestinal obstruction , intraabdominal perianal abscess require surgical drainage GI surgery within 3 month prior receive first dose sargramostim Symptoms bowel obstruction confirm evidence clinically significant stricture within last 6 month surgically correct Use follow medication within 4 week prior receive first dose study drug : 6 mercaptopurine , azathioprine , cyclophosphamide , methotrexate , mycophenolate mofetil , tacrolimus , cyclosporine , thalidomide Use licensed/registered and/or experimental antitumor necrosis factor ( TNF ) therapy infliximab adalimumab within 8 week prior first dose sargramostim Use investigational drug within 4 week 5 halflives ( whichever great ) prior receive first dose sargramostim Concurrent use corticosteroid therapy Crohn 's Disease , exceed dose 60 mg/day ( equivalent ) prednisone Inability comply protocol requirement provide informed consent Presence clinically important comorbid condition ( ) unrelated Crohn 's Disease Prior use recombinant human GMCSF ( sargramostim molgramostim ) granulocyte colonystimulating factor ( GCSF ; filgrastim pegfilgrastim ) Current use nutritional therapy ( i.e. , tube feed elemental/polymeric diet ) provide &gt; 50 % daily caloric intake</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Crohn Disease</keyword>
</DOC>